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Abstract—Accurately identifying distant recurrences in 
breast cancer from the Electronic Health Records (EHR) 
is important for both clinical care and secondary analysis. 
Although multiple applications have been developed for 
computational phenotyping in breast cancer, distant 
recurrence identification still relies heavily on manual 
chart review. In this study, we aim to develop a model that 
identifies distant recurrences in breast cancer using 
clinical narratives and structured data from EHR. We 
apply MetaMap to extract features from clinical 
narratives and also retrieve structured clinical data from 
EHR. Using these features, we train a support vector 
machine model to identify distant recurrences in breast 
cancer patients. We train the model using 1,396 double-
annotated subjects and validate the model using 599 
double-annotated subjects. In addition, we validate the 
model on a set of 4,904 single-annotated subjects as a 
generalization test. We obtained a high area under curve 
(AUC) score of 0.92 (SD=0.01) in the cross-validation using 
the training dataset, then obtained AUC scores of 0.95 and 
0.93 in the held-out test and generalization test using 599 
and 4,904 samples respectively. Our model can accurately 
and efficiently identify distant recurrences in breast 
cancer by combining features extracted from unstructured 
clinical narratives and structured clinical data. 
Keywords—Breast cancer; distant recurrence; 
metastasis; NLP, EHR; computational phenotyping 
I. INTRODUCTION  
Distant recurrences are defined as metastasis of the primary 
breast tumor to lymph nodes or organs beyond the loco-
regional pathological field. Nodes located within the loco-
regional field include ipsilateral axillary, ipsilateral internal 
mammary, supraclavicular, and intramammary lymph nodes 
[1]. Distant lymph nodes beyond the loco-regional field 
include cervical, contralateral axillary, and contralateral 
internal mammary lymph nodes. The most common sites of 
metastasis to organs are the bone, brain, lung, and liver [1]. It 
is important to distinguish between local and distant 
recurrences for several reasons: the categorization informs 
treatment decision-making and directs studies analyzing 
outcomes of local versus distant recurrences. Most 
importantly, the 10-year survival rates are much lower for 
distant recurrences as compared to local recurrences (56% 
after an isolated local recurrence as opposed to 9% after 
distant metastasis) [2]. The delineation can be an important 
prognostic marker for mortality. 
The emerging cancer prognosis research has directed efforts 
towards identifying distant cancer recurrence events 
accurately and efficiently. The National Program of Cancer 
Registries (NPCR) was launched to capture cancer patient 
information and one of its major tasks is to capture disease 
prognosis status for each cancer patient. However, many 
tumor registries fail to accurately identify cancer recurrences 
due to the significant human effort required for data 
maintenance [3, 4]. Manual chart review is one of the 
traditional methods used to identify breast cancer recurrences. 
Unfortunately, chart review is a time-consuming and costly 
process. It limits the number of samples available for research 
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and is not feasible for large cohort studies. Furthermore, it is 
subject to human error in data analysis.  
Computational phenotyping aims to automatically mine or 
predict clinically significant, or scientifically meaningful, 
phenotypes from structured EHR data, unstructured clinical 
narratives, or combination of the two. In this study, we aim to 
develop a model to identify distant recurrences within a cohort 
of breast cancer patients. To develop the model, we utilize 
data collected in Northwestern Medicine Enterprise Data 
Warehouse (NMEDW), which is a joint initiative across the 
Northwestern University Feinberg School of Medicine and 
Northwestern Memorial HealthCare [5]. The NMEDW houses 
the EHR for about 6 million patients. Both structured and 
unstructured data are available in the NMEDW. Structured 
data typically capture patients’ demographic information, lab 
values, medications, diagnoses, and encounters [6]. Although 
readily available and easily accessible, studies have concluded 
that structured data alone are not sufficient to accurately infer 
phenotypes [7, 8]. For example, ICD-9 codes are mainly 
recorded for administrative purposes and are influenced by 
billing requirements and avoidance of liability [9, 10]. 
Consequently, these codes do not always accurately reflect a 
patient’s underlying physiology. Furthermore, not all patient 
information (such as clinicians’ observations and insights) is 
well documented in structured data [11]. As a result, using 
structured data alone for phenotype identification often results 
in low performance [8]. The limitations associated with 
structured data for computational phenotyping have 
encouraged the use of clinical narratives, which typically 
include clinicians’ notes, observations, referring letters, 
specialists’ reports, discharge summaries, and records of 
communication between doctors and patients [12]. These 
clinical narratives contain rich descriptions of patients’ disease 
assessment, history, and treatments. However, the clinical 
narratives are not readily accessible without the use of natural 
language processing (NLP). The abundance of information in 
the free text makes NLP an indispensable tool for text-mining 
[13-15]. 
Our goal is to develop such a system that combines structured 
EHR data and unstructured clinical narratives to accurately 
and efficiently identify distant recurrences in breast cancer. 
Such a model can be easily replicated and requires a minimum 
amount of human effort and input. 
II. RELATED WORK 
Computational phenotyping has facilitated biomedical and 
clinical research across many applications, including patient 
diagnosis categorization, novel phenotype discovery, clinical 
trial screening, pharmacogenomics, drug-drug interaction 
(DDI) and adverse drug event (ADE) detection, and down-
stream genomics studies. Different NLP applications have also 
been developed to identify breast cancer recurrences. Carrell 
et al. [16] proposed a method to identify breast cancer sub-
cohorts with ipsilateral, regional, and metastatic events using 
the concepts identified within the free text. The binary 
classification model achieved an F-measure scores of 0.84 and 
0.82 in the training set and test set, respectively. However, the 
model could not distinguish a local recurrence from a distant 
recurrence. In addition, defining the number of hits in the 
system to segment the documents required substantial effort. 
Using morphology codes and anatomical sites from pathology 
reports, Strauss et al. [17] were able to identify recurrences. 
However, their approach required that the pathology reports 
be well-documented under a standard format. However, the 
majority of distant recurrences in breast cancer have been 
diagnosed clinically rather than pathologically [18]. It has 
been challenging to identify distant recurrences from 
pathology reports because they are not usually recorded as 
clinical diagnoses in the reports. Haque et al. [19] applied a 
hybrid approach to identify breast cancer recurrences using a 
combination of pathology reports and EHR data. They 
achieved a relatively high NPV of 0.995 and a relatively low 
PPV of 0.65. This model also required a minimum amount of 
ten percent manual chart review, which is still fairly time-
consuming. In addition, the model was not able to distinguish 
between local, regional, or distant recurrences. NLP has also 
been applied to attempt retrieving distant recurrences for other 
types of cancer. Lauren et al. [20] tried to identify distant 
recurrences in prostate cancer from clinical notes, radiology 
reports, and pathology reports. They concluded that NLP 
could be used to identify metastatic prostate events more 
accurately than claim data.  
Clinical narratives are known to have high-dimensional 
feature spaces, few irrelevant features, and sparse instance 
vectors [21]. These problems were found to be well-addressed 
by SVMs [21], which also have been recognized for their 
generalizability and are widely used for computational 
phenotyping [13, 22-27]. Carroll et al. [26] implemented a 
SVM model for rheumatoid arthritis identification using a set 
of features from clinical narratives using the Knowledge Map 
Concept Identifier (KMCI) [28]. They demonstrated that a 
SVM algorithm trained on these features outperformed a 
deterministic algorithm. 
A combination of structured data and narratives for 
phenotyping have been found to improve model performances. 
DeLisle et al. [29] implemented a model to identify acute 
respiratory infections. They used structured data combined 
with narrative reports and demonstrated that the inclusion of 
free text improved the PPV score by 0.2–0.7 while retaining 
sensitivities around 0.58-0.75. In a study of the identification 
of methotrexate-induced liver toxicity in patients with 
rheumatoid arthritis, Lin et al. [30] obtained an F-measure of 
0.83 in a performance evaluation. Liao et al. [31] implemented 
a penalized logistic regression as a classification algorithm to 
predict patients’ probabilities of having Crohn’s disease and 
achieved a PPV score of 0.98. Both Lin’s and Liao’s methods 
experimented with a combination of features from structured 
EHR and NLP-processed features from clinical narratives. 
Their studies showed that the inclusion of NLP methods 
resulted in significantly improved performance.  
III. METHODOLOGY 
A. Cohort Description 
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TABLE 1: COHORT DISTRIBUTION IN THE TRAINING AND GENERALIZATION SET 
 Total Distant 
Recurrence  
Percentage (%) Overall percentage 
(%) 
Double-annotated set  1,995 193 9.87% 
9.22% 
Cross-validation set   1,396 138 9.89% 
Held-out test set    599 55 9.19% 
Single-annotated set 4,904 443 9.03 % 
 
Patients diagnosed with breast cancer between 01/01/2001 and 
12/31/2015 are drawn from NMEDW. Patients are identified 
by ICD-9 codes. In total, 19,874 females are included. Within 
this cohort, only cases with at least one surgical pathology 
report documented in the desired time window are selected. In 
total, 6,899 subjects are identified and included in this study. 
The workflow to generate this data set is presented in Figure 
1. 
 
Figure 1: Workflow to identify the cohort 
To establish a gold standard for algorithm development, each 
patient is assigned a definite distant recurrence status (‘Yes’ or 
‘No’) according to manual chart review. In total, 1,995 
subjects are annotated twice by two annotators (co-authors: 
medical student AR; breast surgery fellow SE) and are 
included for model training and validation. The inter-rater 
agreements for the two annotators are measured by Cohen’s 
kappa score, and the obtained score is 0.87 [32]. The items 
without agreements are resolved by a discussion between the 
two annotators. The other 4,904 subjects are annotated once 
by annotators (co-authors: post-doc fellow XL; Ph.D. 
candidate ZZ) and are used as an independent set for model 
generalization test. These annotations are conducted over a 
span of 15 months (completed September 2017).  
The 1,995 double-annotated subjects are randomly split 
into a cross-validation set and a held-out test set according to a 
7:3 ratio. In the cross-validation set, five-fold cross-validation 
is applied with the 1,396 samples. Among these 1,396 samples, 
138 distant recurrence events are identified; among the 599 
samples in held-out test set, 55 distant recurrences are 
identified. In the generalization test set, 443 distant recurrences 
are identified among the 4,904 samples. The cohort distribution 
is shown in TABLE 1. 
B. Structured Clinical Data 
Automated SQL codes are developed to query structured data 
from NMEDW. In total, 18 structured clinical variables are 
retrieved or derived. The variable names and corresponding 
categories or values are displayed in TABLE 2. Demographic 
data such as the age of diagnosis, race, smoking history, 
alcohol usage, family cancer history, and insurance type are 
queried. Smoking history is categorized as ‘Yes’, ‘No’, ‘Ex-
smoker’, or ‘Unknown’. Alcohol usage is categorized as ‘No’, 
‘Moderate’, ’Heavy’, ’Former’, or ‘Unknown’. Tumor 
characteristics and biomarkers, such as estrogen receptor 
(ER), progesterone receptor (PR), HER2, P53, nodal 
positivity, histology, tumor grade, and tumor size are 
retrieved. Nodal positivity is categorized as ‘Positive’, 
‘Negative’, or ‘Unknown’. The variable histology and nodal 
positivity are selected, because subjects with invasive ductal 
breast cancer or positive lymph nodes are more likely to 
develop a distant recurrence compared to those that have 
ductal in situ or negative lymph nodes [33]. Primary surgery 
type is categorized as ‘Breast conservation surgery’, 
‘Mastectomy’, ‘No’, or ‘Unknown’.  
Additional clinical variables are derived to help identify 
distant recurrences. Variables of deceased, targeted therapy, 
and radiation are developed. The deceased variable is a binary 
variable to indicate whether a patient deceased before the age 
of 75. Intuitively, patients with distant recurrences might have 
a shorter survival length compared to the women who do not 
have distant recurrences. After a discussion with a domain 
expert (co-author SK), we choose the age of 75 as the cutoff. 
Another variable ‘targeted therapy’ is a binary variable created 
to indicate whether the patient has taken any of the following 
drugs: ‘Afinitor’, ‘Everolimus’, ‘Bevacizumab’, ‘Avastin’, 
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‘Ibrance’, or ‘Palbociclib’. These drugs are prescriptions for 
patients with distant recurrences. An additional variable 
radiation is a binary variable indicating whether the subject 
has received radiation treatment at the site of metastases, such 
as brain, lung, or bone. This variable is derived from the 
intuition that patients receiving radiation at a site different 
from the primary tumor are at a higher chance of having 
distant recurrences. 
TABLE 2: THE NAME AND CORRESPONDING CATEGORIES (VALUES) OF THE 18 
RETRIEVED STRUCTURED CLINICAL VARIABLES. IDC IS INVASIVE DUCTAL 
CARCINOMA, DCIS IS DUCTAL CARCINOMA IN SITU, ILC IS INVASIVE LOBULAR 
CARCINOMA, NETWORK CATEGORY IS THE NETWORK OF PATIENT’S 
INSURANCE PLAN. 
Variable Name Category 
age of diagnosis  Continuous 
race White, Black, Asian, Other 
smoking history Yes, No, Ex-smoker, Unknown 
alcohol usage No, Moderate, Heavy, Former, 
Unknown 
family cancer history Yes, No, Unknown 
insurance type Network Category 
estrogen receptor Positive, Negative, Unknown 
progesterone receptor Positive, Negative, Unknown 
HER2 Positive, Negative, Unknown 
P53 Positive, Negative, Unknown 
nodal positivity Positive, Negative, or Unknown 
histology IDC, DCIS, ILC, Unknown 
grade Grade1, Grade2, Grade3, 
Unknown 
size 0-2cm, 2cm-5cm, >5cm, Unknown 
surgery type Mastectomy, Breast conservation 
surgery, Unknown 
deceased Yes, No 
targeted therapy Yes, No 
radiation Yes, No 
C. Clinical Narratives 
We query the NMEDW for clinical narratives generated 
before May 2016 (the start time of manual chart review) or the 
date when the patient is censored. All inpatient and outpatient 
notes are retrieved without any provider type restriction. The 
retrieved clinical narratives include progress notes, pathology 
reports, telephone encounter notes, assessment and plan notes, 
problem overview notes, treatment summary notes, radiology 
notes, lab notes, procedural notes, and nursing notes. Only 
notes generated after the diagnosis of breast cancer are 
retrieved. We only include the notes having at least one 
mention of ‘breast’. After retrieving the narratives, we first 
preprocess the corpus by removing duplicate copies, 
tokenizing sentences, and removing non-English symbols. 
Following these preprocessing steps, we annotate the medical 
concepts in the sentences using MetaMap, an NLP application 
to map the biomedical text to the UMLS Metathesaureus [34]. 
The surrounding semantic context is determined. CUIs that are 
tagged as negated by NegEx [35] are excluded (NegEx is a 
negation tool configured in MetaMap). If multiple CUIs are 
mapped, the one with maximum MMI score (a score ranked 
by MetaMap) is retained. In order to completely and 
accurately exclude negations or unrelated contextual cues, 
such as a differential diagnosis event, sentences with negative 
contextual features (e.g., ‘no’, ‘rule out’, ‘deny’, 
‘unremarkable’) and uncertain contextual features (e.g., ‘risk’, 
‘concern’, ‘worry’, ‘evaluation’) are also removed. This 
customized list of contextual features is obtained from the 
development corpus. 
D. Feature Generation 
To focus our NLP efforts, we identify a set of target distant 
recurrence concepts with the help of sample notes. We review 
a development corpus of ten randomly selected samples’ notes 
with distant recurrences and extract partial sentences that are 
related to a breast cancer distant recurrence. These extracted 
partial sentences appear in TABLE S1. The initial set contains 
20 partial sentences. These partial sentences are tagged by 
MetaMap, and the CUIs corresponding to each concept is 
obtained. The customized dictionary contains 83 CUIs 
(TABLE S2). After data preprocessing and concept mapping, 
only CUIs with highest MMI score that also fall within the 
customized dictionary are used as features for model training. 
CUIs with MMI score smaller than one are filtered and 
excluded. Following this feature selection, there are 83 
narrative-based features remaining for inclusion in the 
machine learning algorithm. In addition to the obtained CUI 
features, the 18 structured clinical variables described above 
are used as additional features. 
E. Prediction Model and Evaluation 
We use support vector machine (SVM) to develop an 
algorithm to predict whether patients had distant recurrences. 
SVMs have been widely used for computational phenotyping 
[13, 22-27]. We apply linear kernel type for the SVM models. 
In our experiments, we train four baseline classifiers on 
different feature types: a full set of medical concepts tagged 
by MetaMap [34], a filtered set of medical concepts tagged by 
MetaMap, only the structured clinical data, and a standard bag 
of words from clinical narratives. TfIDFVectorizer class in 
scikit-learn is used to convert the raw documents to a matrix 
of TF-IDF features to assemble a bag of words. In the full 
MetaMap and bag of words, Chi-square test is applied to 
select features before training the model to remove the 
common words that exist in clinical narratives. Only top 5% 
features are retained for modeling.  
In the model evaluation, we choose area under curve (AUC) 
score as a measurement metric because this is a skewed cohort 
with low event rate. The output of our SVM model is 
probabilities, though in practice, various thresholds result in 
different true positive/false positive rates and AUC score 
considers all possible thresholds. To better demonstrate the 
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TABLE 3: DESCRIPTIVE SUMMARIES OF 1,995 SUBJECTS’ CLINICAL DATA. THE SIGNIFICANCE TEST IS PERFORMED BETWEEN THE RECURRENCE GROUP AND THE 
NON-RECURRENCE GROUP. ONLY DATA WITH P-VALUES LESS THAN 0.05 ARE PRESENTED. DR STANDS FOR DISTANT RECURRENCE. THE MEAN AND STANDARD 
DEVIATION ARE CALCULATED FOR CONTINUOUS VARIABLES. NUMBERS AND PERCENTAGES ARE PRESENTED FOR CATEGORICAL VARIABLES. P-VALUES ARE 
OBTAINED USING STUDENT’S T-TEST FOR CONTINUOUS VARIABLES AND CHI-SQUARED TEST FOR CATEGORICAL VARIABLES.  
 Double-annotated set 
N=1,995 
DR  
N=193  
No DR  
N=1,802 
 
P-value  
Nodal positivity (%) 544 (27.3%)  103 (53.4%) 441 (24.5%) 1.4e-14 
Histology (%)     2.6e-06 
 IDC                 1,530 (76.7%)          174 (90.2%) 1,356 (75.2%)  
DCIS                279 (14.0%)        3 (1.6%) 276 (15.3%)  
ILC                155 (7.8%)       15 (7.8%) 140 (7.8%)  
Grade (%)     2.1e-10 
Grade 1           458 (23.0%)          16 (8.3%) 442 (24.5%)  
Grade 2          851 (42.7%)        73 (37.8%) 778 (43.2%)  
Grade 3         665 (33.3%)       101 (52.3%) 564 (31.3%)  
Deceased (%)  157 (7.9%) 98 (50.8%) 59 (3.3%) < 2.2e-16 
Radiation (%)  67 (3.4%) 52 (26.9%) 15 (0.8%) < 2.2e-16 
Targeted therapy (%) 60 (3.0%) 44 (22.8%) 16 (0.9%) < 2.2e-16 
 
thresholds and model performance, the corresponding receiver 
operating characteristic (ROC) curves for the different 
methods are evaluated. Cross validation performance depends 
on the randomly shuffled split of the training dataset into 
multiple folds. In order to obtain robust performance statistics, 
each five-fold cross validation is replicated 20 times using 
shuffled stratified splits initialized with different random 
seeds. 
IV. EXPERIMENT RESULTS 
As demonstrated in TABLE 3, clinical data with a significant 
difference between the recurrence group and the non-
recurrence group in the double-annotated training set are 
presented. Compared to the non-recurrence patients, women 
with recurrences had a higher percentage of nodal positivity 
and higher grade of tumor, were more likely to be diagnosed 
with invasive ductal carcinomas, had more radiation 
performed at the metastasis site, had received more targeted 
therapies, and were more likely to die before the age of 75. 
Using SVM as a prediction model, the AUC scores 
obtained from the cross-validation are reported in TABLE 4. 
To note, the model applied was an SVM model with linear 
kernel (C equaled 1, and gamma was set as ‘auto’ in the python 
package ‘sklearn.svm’). The AUC score obtained in our 
proposed model was 0.92 (SD=0.01). The performance of our 
proposed model significantly outperformed the other four 
baselines. The P-value for Student’s t-test was 0.0004 
comparing our proposed model with the second-ranked model 
of Filtered MetaMap. 
To illustrate, the corresponding receiver operating 
characteristic (ROC) curves for the different methods are 
plotted in Figure 2. 
 
TABLE 4: THE NUMBER OF FEATURES AND THE AUC SCORES OBTAINED IN 
THE CROSS-VALIDATION USING 70% OF THE GROUND TRUTH DATA.  
Model Number of Features AUC (SD) 
Filtered MetaMap 
+Clinical Data  
101 0.92 (  
Full MetaMap  1,537 0.78 (0.04) 
Filtered MetaMap  83 0.90 (  
Clinical Data  18 0.77 (  
Bag of Words  4,959 0.82 (0.02) 
We trained an SVM model on the training set (1,396 samples) 
and then predicted labels on the held-out test set (599 
samples). Comparing the predicted probabilities and the 
annotated labels, the obtained AUC scores are presented in 
TABLE 5. The AUC score obtained in our proposed model 
was 0.95. The model with NLP-features, Filtered MetaMap 
also had a notable performance of 0.93. The performance in 
our proposed model again outperformed all the baseline 
models. 
TABLE 5: THE NUMBER OF FEATURES AND THE AUC SCORES OBTAINED IN 
THE EXTERNAL TEST USING THE TEST SET (599 SAMPLES).  
Model AUC 
Filtered MetaMap + Clinical Data  0.95 
Full MetaMap  0.56 
Filtered MetaMap  0.93 
Clinical Data  0.87 
Bag of Words  0.55 
In addition to our training and validation analyses, we applied 
our fitted model to predict labels on the generalization set, 
which contained 4,904 single-annotated samples. In this 
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Figure 2: Receiver operating characteristic (ROC) curves using different methods. Each experiment is replicated 20 times using different shuffled stratified splits 
and all derived ROC curves are plotted. 
 
TABLE 6: TOP 15 VARIABLES WITH THEIR CORRESPONDING COEFFICIENTS 
CUI Name Coefficient Partial Sentences 
C0153678 Secondary malignant neoplasm 
of pleura 
1.00 cancer metastatic to pleura metastatic cancer 
to pleura 
Radiation  Clinical Variable 0.90  
Deceased Clinical Variable 0.90  
Targeted therapy Clinical Variable 0.84  
C0153690 Secondary malignant neoplasm 
of bone 
0.76 metastases to bone, bone metastases 
C1967552 IXEMPRA 0.71 ixempra 
C0278488 Carcinoma breast stage IV 0.70 metastatic breast cancer, breast cancer stage 
iv, metastatic breast carcinoma 
C0494165 Secondary malignant neoplasm 
of liver 
0.62 liver metastases, liver metastatic disease, 
metastatic disease liver, metastases to the 
liver, liver metastases 
C0220650 Metastatic malignant neoplasm 
to brain 
0.59 brain metastases 
C1266909 Entire bony skeleton 0.39 bone 
C2939420 Metastatic Neoplasm 0.27 metastatic disease 
C0036525 Metastatic to 0.25 metastatic 
C0027627 Neoplasm Metastasis 0.25 metastatic disease 
C0346993 Secondary malignant neoplasm 
of female breast 
0.23 metastatic breast cancer to the 
C1522484 Metastatic qualifier 0.22 metastatic 
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generalization test, we obtained an AUC score of 0.93, which 
had a similar performance as the held-out test.  
From the fitted SVM model using the 1,396 samples in the 
training set, we retrieved the coefficient scores for each 
feature. The top 15 ranked coefficient scores and their 
corresponding variable names appear in TABLE 6. Three of 
the clinical variables (radiation, deceased, and targeted 
therapy) were highly ranked on the list. These three variables 
were treatment or outcome variables. The rest of the top-
ranked features were concepts obtained from clinical 
narratives. Most of the CUIs were either related to metastases 
events or related to the metastatic sites that breast cancer could 
spread to. The term ‘IXEMPRA’ is a prescription medicine 
used for locally advanced breast cancer or breast cancer with 
distant recurrences.  
V. DISCUSSION 
In this study, we combined 83 features from unstructured 
clinical narratives and 18 features from structured clinical data 
to identify distant recurrences in breast cancer. Clinical 
narratives were extracted from progress notes, pathology 
reports, telephone encounter notes, assessment and plan notes, 
problem overview notes, treatment summary notes, radiology 
notes, lab notes, procedural notes, and nursing notes generated 
after diagnosis of primary breast cancer. The clinical 
narratives were tagged by NLP application MetaMap to 
generate UMLS concepts. After filtering out concepts that 
were not in the customized dictionary, the remaining concepts 
were combined with the structured clinical data to train an 
SVM model for distant recurrence identification. We were 
able to identify structured clinical variables that could stratify 
the groups of women with and without distant recurrences. 
Using such a method, we obtained an AUC score of 0.95 and 
0.93 in our external held-out test and generalization test. 
During the feature coefficient study, we found that the features 
“secondary malignant neoplasm of pleura, radiation, deceased, 
targeted therapy, and secondary malignant neoplasm of bone” 
were the top-ranked features. Intuitively, women with distant 
recurrences have a higher chance of receiving radiation at the 
metastatic site and of receiving targeted therapy compared to 
those without distant recurrences. They are also more likely to 
have a lower survival rate. The most common sites of 
metastasis to organs were the bone, brain, lung, and liver [1]. 
In our study, we found the mentions of metastatic to bone, 
liver, and brain were also top-ranked. The terms ‘metastatic’ 
and ‘breast cancer’ were also more likely to appear in the 
clinical notes of patients with distant recurrences.  
Progress notes are notably telegraphic. Also, many excessively 
busy residents and senior clinicians create notes by simply 
copying and pasting previous encounter notes, while making 
only minor updates for the most recent appointment. This 
results in many notes that differ in ‘critical’ content still 
scoring highly on the overall measures of similarity. The same 
applies to the full set of MetaMap concepts, which is similar to 
the bag of words. To include only highly associated features in 
our model, we removed the common concepts or words in the 
notes. Chi-square test was applied to select features before 
training the model. Only the top 5% features were retained for 
full MetaMap and bag of words modeling. This test might 
have the potential for overfitting in cross-validations. Indeed, 
we saw a lower performance in the held-out test for full 
MetaMap and bag of words. To adjust this problem, we tested 
different thresholds for the Chi-square test selection. However, 
we found 5% ended with the best results.  
Identifying breast cancer distant recurrence in clinical data sets 
is important for clinical research and practice. Annotation of 
distant recurrence is difficult using standard EHR phenotyping 
approaches and are commonly beyond the scope of manual 
annotation efforts by cancer registries. A model using natural 
language processing, EHR data, and machine learning to 
identify distant recurrences in breast cancer patients allows 
more accurate data-mining and significantly less time-
consuming manual chart review. We expect that by minimally 
adapting the positive concept set, this study has the potential 
to be replicated at other institutions with a moderately sized 
training dataset. In this study, we generated features using 
sentences extracted from the clinical narratives combined with 
structured data. The training and testing data sets were cross-
annotated in the process, which offered a solid ground truth 
for the study. Replicating this model requires minimal outside 
effort. We offered the customized dictionary in this study, so a 
user can retrieve the required notes and clinical structured data 
in order to replicate this study. After the rigorous manual chart 
review and feature retrieval, our data set has offered a gold-
standard data set with rich, validated information for further 
breast cancer research.  
When replicating this study at another institution, there is a 
chance that one will not be able to find the structured clinical 
data in their databases. If this is the case, some of the 
structured data can be found from other resources. Variables 
of ‘histology’ and ‘lymph node status’ can be extracted from 
pathology reports using a rule-based system. For example, 
expressions of ‘total lymph nodes’, ‘total lymph nodes number 
positive’, ‘axillary lymph nodes examined’, ‘axillary lymph 
nodes examined number of positive versus total’ can be used 
to extract lymph node status from pathology report at our 
institution. Survival information can be found in the 
administrative billing system.  
VI. FUTURE WORK 
The NLP pipeline cannot characterize the context of features. 
Clinical narratives contain patients’ concerns, clinicians’ 
assumptions, and patients’ past medical histories. Clinicians 
also record diagnoses that are ruled out or symptoms that 
patients denied. Our next aim will be that such conditions, 
mentions, and feature relations will be extracted to better 
distinguish differential diagnoses. Generalized relation and 
event extraction, rather than binary relation classification, will 
be conducted. To this end, graph methods are a promising 
class of algorithms and should be actively investigated [36, 
37].  
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In the future, we will test our data with different machine 
learning models. In this study, we have chosen SVM model 
with linear kernel for interpretation purposes. Other models 
might result in better performance.  
We will also aim to address the heterogeneity problem in 
clinical narratives. It is a common problem in clinical 
narratives due to the variance in physicians’ expertise and 
behaviors [38]. Features derived from clinical narratives 
included in this study were extracted from notes generated by 
clinicians with different specialties and professional levels of 
expertise. As a result, some content was not relevant to the 
breast cancer distant recurrence event, even though we had 
limited the notes to include the mention of ‘breast’. For 
example, a liver cancer metastasis to the breast from a  primary 
liver tumor would be difficult to identify. We will need to 
resolve the heterogeneity in clinical narratives.  
VII. CONCLUSIONS 
We developed a machine learning model by combining 
structured clinical data and unstructured clinical narratives in 
order to identify distant recurrence events in breast cancer. We 
demonstrated the high accuracy and efficiency of our model, 
using cross-validation, held-out test evaluation, and a further 
generalization set evaluation. Our proposed model allows for 
more accurate and efficient identification of distant recurrences 
than single modality models using either clinical narratives or 
structured clinical data. Thus, our model is a significantly less 
time-consuming and practical alternative to manual chart 
review. This is particularly relevant in an era when evidence-
based medicine receives growing attention and there is more 
emphasis on computational phenotyping and data-driven 
discovery. This model would also be valuable and applicable to 
research in other medical fields beyond breast cancer. 
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